The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma.
Tumor associated glycoprotein 72 (TAG-72) is a membrane-bound glycoprotein complex that is overexpressed in many adenocarcinomas. Recently, monoclonal antibody targeting TAG72, minretumomab, have been introduced as a potential therapeutic target in colorectal cancers (CRC) as well as breast and lung cancers. However, the detailed expression profile of TAG72 and its prognostic effect in CRC are not clear yet. We investigated the relationship between tumor associated glycoprotein 72 (TAG-72) expression and clinicopathologic characteristics in CRC using 3E8 antibody, a fully humanized antibody with the highest affinity to TAG-72. Immunohistochemical staining for TAG-72 was performed in 578 CRC patients, and the results were analyzed using a modified Remmele scoring system (score: 0-12). Of the 578 patients, 144 (24.9%) composed the TAG-72 overexpression (TAG-72high) group. TAG-72high was significantly associated with microsatellite stable tumor (P = .002), lymphatic invasion (P = .001), venous invasion (P = .005), and high pN status (P < .001). In survival analyses, TAG-72high group showed shorter disease-free survival in univariate analysis (P = .001), and TAG-72high was found to be an independent prognostic factor in multivariate analysis (P = .028), in addition to TNM stage. In conclusion, TAG-72 is thought to be the factors involved in the progression of CRC and may be considered as one of the potential therapeutic target.